PRAX gets FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor

Praxis Precision Medicines, Inc.

Ulixacaltamide granted BTD for treatment of essential tremor based on Essential3 Phase 3 data.
BTD enables expedited development and regulatory review for serious condition.
Positive topline data from two pivotal Phase 3 studies supported the designation.
Essential tremor affects millions; ulixacaltamide may show substantial improvement over available therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.